{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:32:05Z","timestamp":1788867125152,"version":"build-2803163510"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The management of asthma and chronic obstructive pulmonary disease (COPD) poses considerable challenges due to the intricate nature of these respiratory conditions. Fostair\u2122 and Trimbow\u2122, two pressurized metered dose inhalers, have emerged as noteworthy therapeutic options for treating both asthma and COPD. Fostair combines an inhaled corticosteroid, specifically beclometasone dipropionate, with a long-acting beta2-agonist, formoterol fumarate dihydrate, offering a dual-action approach to mitigate airway inflammation and bronchoconstriction. Conversely, Trimbow integrates a tri-particulate formulation consisting of beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide, providing a comprehensive strategy to target the pathophysiology of COPD and asthma. Recent clinical trials have underscored Trimbow\u2019s superior efficacy compared with Fostair, particularly in terms of reducing exacerbation rates and enhancing lung function. However, despite their therapeutic promise, both inhalers encounter challenges, including limited generalizability of study findings and a disparity between in vitro and human trial results. This literature review offers an in-depth analysis of Fostair and Trimbow, delving into their mechanisms of action, clinical applications, and outcomes in human studies for asthma and COPD. Additionally, the review discusses the role of combination therapy in managing respiratory diseases and underscores the necessity for further research to address existing knowledge gaps and optimize therapeutic outcomes.<\/jats:p>","DOI":"10.1093\/jpp\/rgae090","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T23:13:21Z","timestamp":1719962001000},"page":"1301-1309","source":"Crossref","is-referenced-by-count":6,"title":["Advances in inhaler therapy for asthma and chronic obstructive pulmonary disease: a comprehensive review of Fostair\u2122 and Trimbow\u2122"],"prefix":"10.1093","volume":"76","author":[{"given":"Katie","family":"Foster","sequence":"first","affiliation":[{"name":"Department of Life Sciences, University of Bath , Bath , BA2 7AY,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6132-6432","authenticated-orcid":false,"given":"Chun Yuen Jerry","family":"Wong","sequence":"additional","affiliation":[{"name":"Respiratory Technology, Woolcock Institute of Medical Research , Sydney, NSW 2037 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health Sciences, Macquarie Medical School, Macquarie University , Sydney, NSW 2109 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"2024100305514781800_CIT0001","year":"2019"},{"key":"2024100305514781800_CIT0002","author":"Emc","year":"2019"},{"key":"2024100305514781800_CIT0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta5260","article-title":"Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature","volume":"5","author":"Brocklebank","year":"2001","journal-title":"Health Technol Assess"},{"key":"2024100305514781800_CIT0004","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.rmed.2011.01.005","article-title":"Inhaler mishandling remains common in real life and is associated with reduced disease control","volume":"105","author":"Melani","year":"2011","journal-title":"Respir Med"},{"key":"2024100305514781800_CIT0005","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2147\/TCRM.S160365","article-title":"Choosing the right inhaler for your asthma or COPD patient","volume":"15","author":"Usmani","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"2024100305514781800_CIT0006","author":"NHS","year":"2021"},{"key":"2024100305514781800_CIT0007","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1056\/NEJMra054308","article-title":"The asthma epidemic","volume":"355","author":"Eder","year":"2006","journal-title":"N Engl J Med"},{"key":"2024100305514781800_CIT0008","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3389\/fped.2019.00246","article-title":"Epidemiology of asthma in children and adults","volume":"7","author":"Dharmage","year":"2019","journal-title":"Front Pediatr"},{"key":"2024100305514781800_CIT0009","volume-title":"Asthma statistics | British Lung Foundation [Internet]","author":"British Lung Foundation","year":"2013"},{"key":"2024100305514781800_CIT0010","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","journal-title":"Lancet"},{"key":"2024100305514781800_CIT0011","author":"Global Initiative for Asthma","year":"2022"},{"key":"2024100305514781800_CIT0012","author":"Global Initiative for Chronic Obstructive Lung Disease","year":"2020"},{"key":"2024100305514781800_CIT0013","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1183\/09059180.00003609","article-title":"Epidemiology of COPD","volume":"18","author":"Raherison","year":"2009","journal-title":"Eur Respir Rev."},{"key":"2024100305514781800_CIT0014","author":"Global Initiative for Chronic Obstructive Lung Disease","year":"2022"},{"key":"2024100305514781800_CIT0015","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/0003-4819-142-4-200502150-00005","article-title":"The effects of a smoking cessation intervention on 14.5-year mortality","volume":"142","author":"Anthonisen","year":"2005","journal-title":"Ann Intern Med"},{"key":"2024100305514781800_CIT0016","author":"NICE","year":"2019"},{"key":"2024100305514781800_CIT0017","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3111\/13696998.2011.594123","article-title":"Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers","volume":"14","author":"Yu","year":"2011","journal-title":"J Med Econ"},{"key":"2024100305514781800_CIT0018","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1378\/chest.128.5.3198","article-title":"Factors associated with medication nonadherence in patients with COPD","volume":"128","author":"George","year":"2005","journal-title":"Chest"},{"key":"2024100305514781800_CIT0019","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/thx.2009.113662","article-title":"Adherence to inhaled therapy, mortality and hospital admission in COPD","volume":"64","author":"Vestbo","year":"2009","journal-title":"Thorax"},{"key":"2024100305514781800_CIT0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3399\/bjgp08X263802","article-title":"Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help","volume":"58","author":"Sovani","year":"2008","journal-title":"Br J Gen Pract."},{"key":"2024100305514781800_CIT0021","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199711133372001","article-title":"Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group","volume":"337","author":"Pauwels","year":"1997","journal-title":"N Engl J Med"},{"key":"2024100305514781800_CIT0022","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jaci.2011.12.974","article-title":"The relationship between combination inhaled corticosteroid and long-acting \u03b2-agonist use and severe asthma exacerbations in a diverse population","volume":"129","author":"Wells","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"2024100305514781800_CIT0023","first-page":"682","article-title":"A pooled analysis of FEV 1 decline in COPD patients randomized to inhaled corticosteroids or placebo","author":"Soriano","year":"2007"},{"key":"2024100305514781800_CIT0024","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/15412550802363360","article-title":"Anti-inflammatory effects of combined budesonide\/formoterol in COPD exacerbations","volume":"5","author":"Bathoorn","year":"2008","journal-title":"COPD"},{"key":"2024100305514781800_CIT0025","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1074\/jbc.274.2.1005","article-title":"Ligand-independent activation of the glucocorticoid receptor by \u03b22-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells","volume":"274","author":"Eickelberg","year":"1999","journal-title":"J Biol Chem"},{"key":"2024100305514781800_CIT0026","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","article-title":"Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet (London, England)"},{"key":"2024100305514781800_CIT0027","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet (London, England)"},{"key":"2024100305514781800_CIT0028","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet (London, England)"},{"key":"2024100305514781800_CIT0029","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(19)32215-9","article-title":"Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials","volume":"394","author":"Virchow","year":"2019","journal-title":"Lancet (London, England)"},{"key":"2024100305514781800_CIT0030","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.rmed.2010.09.008","article-title":"Beclomethasone\/formoterol in the management of COPD: a randomised controlled trial","volume":"104","author":"Calverley","year":"2010","journal-title":"Respir Med"},{"key":"2024100305514781800_CIT0031","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.rmed.2014.05.013","article-title":"Extrafine beclomethasone\/formoterol in severe COPD patients with history of exacerbations","volume":"108","author":"Wedzicha","year":"2014","journal-title":"Respir Med"},{"key":"2024100305514781800_CIT0032","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2466-14-43","article-title":"Extrafine beclomethasone\/formoterol compared to fluticasone\/salmeterol combination therapy in COPD","volume":"14","author":"Singh","year":"2014","journal-title":"BMC Pulmonary Med"},{"key":"2024100305514781800_CIT0033","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.rmed.2008.09.002","article-title":"Lung function and asthma control with beclomethasone and formoterol in a single inhaler","volume":"103","author":"Huchon","year":"2009","journal-title":"Respir Med"},{"key":"2024100305514781800_CIT0034","year":"2023"},{"key":"2024100305514781800_CIT0035","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1016\/S2213-2600(13)70012-2","article-title":"Beclometasone\u2013formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial","volume":"1","author":"Papi","year":"2013","journal-title":"Lancet Respiratory Med"},{"key":"2024100305514781800_CIT0036","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1440-1843.2006.00856.x","article-title":"Efficacy and safety of high-dose budesonide\/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma","volume":"11","author":"Jenkins","year":"2006","journal-title":"Respirology (Carlton, Vic.)"},{"key":"2024100305514781800_CIT0037","doi-asserted-by":"crossref","first-page":"124009","DOI":"10.1016\/j.ijpharm.2024.124009","article-title":"Nasal delivery of encapsulated recombinant ACE2 as a prophylactic drug for SARS-CoV-2","volume":"655","author":"Baldelli","year":"2024","journal-title":"Int J Pharm"},{"key":"2024100305514781800_CIT0038","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1007\/s13346-024-01558-1","article-title":"Insulin delivery to the brain via the nasal route: unraveling the potential for Alzheimer\u2019s Disease therapy","volume":"14","author":"Wong","year":"2024","journal-title":"Drug Deliv Transl Res"},{"key":"2024100305514781800_CIT0039","doi-asserted-by":"crossref","first-page":"123922","DOI":"10.1016\/j.ijpharm.2024.123922","article-title":"An overview of in vitro and in vivo techniques for characterization of intranasal protein and peptide formulations for brain targeting","volume":"654","author":"Wong","year":"2024","journal-title":"Int J Pharm"},{"key":"2024100305514781800_CIT0040","doi-asserted-by":"crossref","first-page":"104848","DOI":"10.1016\/j.jddst.2023.104848","article-title":"Impact of amino acids on the properties of nasal dry powders","volume":"87","author":"Baldelli","year":"2023","journal-title":"J Drug Delivery Sci Technol"},{"key":"2024100305514781800_CIT0041","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/17425247.2023.2231850","article-title":"Advances in soft mist inhalers","volume":"20","author":"Komalla","year":"2023","journal-title":"Expert Opin Drug Deliv"},{"key":"2024100305514781800_CIT0042","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejpb.2023.06.015","article-title":"Engineered dry powders for the nose-to-brain delivery of transforming growth factor-beta","volume":"189","author":"Wong","year":"2023","journal-title":"Eur J Pharm Biopharm"},{"key":"2024100305514781800_CIT0043","doi-asserted-by":"crossref","first-page":"122667","DOI":"10.1016\/j.ijpharm.2023.122667","article-title":"Microfluidics assembly of inhalable liposomal ciprofloxacin characterised by an innovative in vitro pulmonary model","volume":"635","author":"Zhang","year":"2023","journal-title":"Int J Pharm"},{"key":"2024100305514781800_CIT0044","doi-asserted-by":"crossref","first-page":"122024","DOI":"10.1016\/j.ijpharm.2022.122024","article-title":"Validation of a cell integrated next-generation impactor to assess in vitro drug transport of physiologically relevant aerosolised particles","volume":"624","author":"Wong","year":"2022","journal-title":"Int J Pharm"},{"key":"2024100305514781800_CIT0045","doi-asserted-by":"crossref","first-page":"121989","DOI":"10.1016\/j.ijpharm.2022.121989","article-title":"Development of excipients free inhalable co-spray-dried tobramycin and diclofenac formulations for cystic fibrosis using two and three fluid nozzles","volume":"624","author":"Marasini","year":"2022","journal-title":"Int J Pharm"},{"key":"2024100305514781800_CIT0046","doi-asserted-by":"crossref","first-page":"120487","DOI":"10.1016\/j.lfs.2022.120487","article-title":"The application of in vitro cellular assays for analysis of electronic cigarettes impact on the airway","volume":"298","author":"Wong","year":"2022","journal-title":"Life Sci"},{"key":"2024100305514781800_CIT0047","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/17425247.2022.2026922","article-title":"Combining experimental and computational techniques to understand and improve dry powder inhalers","volume":"19","author":"Chaugule","year":"2022","journal-title":"Expert Opin Drug Deliv"},{"key":"2024100305514781800_CIT0048","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/jpp\/rgaa052","article-title":"\u03b2-Cyclodextrin-containing chitosan-oligonucleotide nanoparticles improve insulin bioactivity, gut cellular permeation and glucose consumption","volume":"73","author":"Wong","year":"2021","journal-title":"J Pharm Pharmacol"},{"key":"2024100305514781800_CIT0049","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/1061186X.2020.1817042","article-title":"Fabrication techniques for the preparation of orally administered insulin nanoparticles","volume":"29","author":"Wong","year":"2021","journal-title":"J Drug Target"},{"key":"2024100305514781800_CIT0050","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1111\/jphp.13359","article-title":"C2C12 cell model: its role in understanding of insulin resistance at the molecular level and pharmaceutical development at the preclinical stage","volume":"72","author":"Wong","year":"2020","journal-title":"J Pharm Pharmacol"},{"key":"2024100305514781800_CIT0051","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/03639045.2020.1788061","article-title":"Development of orally administered insulin-loaded polymeric-oligonucleotide nanoparticles: statistical optimization and physicochemical characterization","volume":"46","author":"Wong","year":"2020","journal-title":"Drug Dev Ind Pharm"},{"key":"2024100305514781800_CIT0052","doi-asserted-by":"crossref","first-page":"101738","DOI":"10.1016\/j.jddst.2020.101738","article-title":"Formulation and characterisation of insulin-loaded chitosan nanoparticles capable of inducing glucose uptake in skeletal muscle cells in vitro","volume":"57","author":"Wong","year":"2020","journal-title":"J Drug Delivery Sci Technol"},{"key":"2024100305514781800_CIT0053","doi-asserted-by":"crossref","first-page":"118720","DOI":"10.1016\/j.ijpharm.2019.118720","article-title":"Bio-nanotechnological advancement of orally administered insulin nanoparticles: comprehensive review of experimental design for physicochemical characterization","volume":"572","author":"Wong","year":"2019","journal-title":"Int J Pharm"},{"key":"2024100305514781800_CIT0054","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.1007\/s00216-018-1319-9","article-title":"Quantification of BSA-loaded chitosan\/oligonucleotide nanoparticles using reverse-phase high-performance liquid chromatography","volume":"410","author":"Wong","year":"2018","journal-title":"Anal Bioanal Chem"},{"key":"2024100305514781800_CIT0055","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijpharm.2018.07.041","article-title":"Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus","volume":"549","author":"Wong","year":"2018","journal-title":"Int J Pharm"},{"key":"2024100305514781800_CIT0056","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/1061186X.2017.1400552","article-title":"The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation","volume":"26","author":"Wong","year":"2018","journal-title":"J Drug Target"},{"key":"2024100305514781800_CIT0057","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2017.09.003","article-title":"Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment","volume":"264","author":"Wong","year":"2017","journal-title":"J Control Release."},{"key":"2024100305514781800_CIT0058","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/jphp.12694","article-title":"In-vitro evaluation of enteric coated insulin tablets containing absorption enhancer and enzyme inhibitor","volume":"69","author":"Wong","year":"2017","journal-title":"J Pharm Pharmacol"},{"key":"2024100305514781800_CIT0059","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/jphp.12607","article-title":"Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities","volume":"68","author":"Wong","year":"2016","journal-title":"J Pharm Pharmacol"},{"key":"2024100305514781800_CIT0060","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/1061186X.2020.1759078","article-title":"Current status and applications of animal models in pre-clinical development of orally administered insulin-loaded nanoparticles","volume":"28","author":"Wong","year":"2020","journal-title":"J Drug Target"},{"key":"2024100305514781800_CIT0061","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/1061186X.2020.1726356","article-title":"Cellular assays and applied technologies for characterisation of orally administered protein nanoparticles: a systematic review","volume":"28","author":"Wong","year":"2020","journal-title":"J Drug Target"},{"key":"2024100305514781800_CIT0062","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1208\/s12249-020-01648-6","article-title":"Lyophilisation improves bioactivity and stability of insulin-loaded polymeric-oligonucleotide nanoparticles for diabetes treatment","volume":"21","author":"Wong","year":"2020","journal-title":"AAPS Pharmscitech"},{"key":"2024100305514781800_CIT0063","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijpharm.2017.12.036","article-title":"Microparticles, microcapsules and microspheres: a review of recent developments and prospects for oral delivery of insulin","volume":"537","author":"Wong","year":"2018","journal-title":"Int J Pharm"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/76\/10\/1301\/59342014\/rgae090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/76\/10\/1301\/59342014\/rgae090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T05:52:05Z","timestamp":1727934725000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/76\/10\/1301\/7703268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":63,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,7,2]]},"published-print":{"date-parts":[[2024,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgae090","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,7,2]]}}}